[A case of malignant hemangioendothelioma effectively treated with intra-arterial continuous infusion of interleukin-2].

Abstract

An 82-year-old female presented with a tumor in the right-frontal region and was diagnosed as MHE, based on the clinical and pathological findings. Increased LAK (lymphokine-activated killer cell) activity was observed during treatment with intraarterial continuous infusion of rIL-2. In addition, the decrease in tumor size was started when LAK activity became high. Treatments for MHE and mechanism of these therapies were discussed using data from this case and other authors' reports.

• Authors: A Fujioka, M Sugitani, Z Suzuki, J Tokita, K Yorimitsu, Y Sezai
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 18 Issue 11 Pg. 1958-61 (Aug 1991) ISSN: 0385-0684 [Print] Japan
• PMID: 1877838 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Interleukin-2
• Recombinant Proteins

Topics

• Aged
• Aged, 80 and over
• Female
• Head and Neck Neoplasms (immunology, pathology, therapy)
• Hemangioendothelioma (immunology, pathology, therapy)
• Humans
• Infusions, Intra-Arterial
• Interleukin-2 (administration & dosage)
• Killer Cells, Lymphokine-Activated (immunology)
• Recombinant Proteins (administration & dosage)